Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00267956 · ClinicalTrials.gov registry record · Phase 2
An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis
A Phase 2 study, sponsored by Centocor.
- Completed
- Registry status
- Phase 2
- Development phase
- 146
- Enrollment target
NCT00267956 is a Phase 2 study that has completed, run by Centocor. The registered enrollment target is 146 participants.
The verdict
NCT00267956, a Phase 2 study, has completed, sponsored by Centocor.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 146 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.
Interventions
- DRUG Placebo
- DRUG CNTO 1275 63 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 146 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00267956
The ClinicalTrials.gov registry entry for NCT00267956 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 146 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centocor, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00267956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00267956 about?
NCT00267956 is a clinical study titled "An Effectiveness and Safety Study of CNTO 1275 in Patients With Active Psoriatic Arthritis". The purpose of this study is to evaluate the effectiveness and safety of CNTO 1275 (ustekinumab) in patients with psoriatic arthritis.
What is the current status of trial NCT00267956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 146 participants. The study started on 2005-12. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00267956?
The interventions under investigation include: Placebo (DRUG), CNTO 1275 63 mg (DRUG).
Who is sponsoring clinical trial NCT00267956?
This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.